Anavex Life Sciences Corp (AVXL)

[hfb46]

My comment is based upon the premise that we continue to get good results as data continues to be released, and that we do indeed attract the attention of some BP companies. I would be very surprised if management would agree to a buy out. The compounds in our pipeline have too much potential for too many CNS conditions, to "sell the store" so early in the game. Of course a deal COULD be struck where AVXL retains the rights to a certain percentage of potential profits going forward, assuming a compound is successful in the market place. But those types of deals can be cumbersome and many companies shy away from such. Also, a deal could be structured whereby the rights to one compound is sold, and thus allowing for the sale proceeds to fund studies in one of our other compounds. But I would think that at this time, Missling is focused on obtaining a "partner", not a "buyer". JMO